Vote in the European Parliament

Laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024/795

Tomislav Sokol – After recital 22 – Am 247
Date: 20.01.2026·Reference: A10-0272/2025
Rapporteur: Tomislav Sokol

Overall Result

Rejected
  • 224 For
  • 424 Against
  • 20 Abstention
  • 51 Did not vote
Amendment— You are viewing a sub-vote (amendment) of the main vote.Amendment 247 · Draft legislative act · Tabled by The LeftView amendment at the EP ↗
Amendment wording

Tabled by Catarina Martins

Added: (22 a) On 9 March 2025, 11 Union Health Ministers signed a letter stating that the Critical Medicines Act must be expanded into an effective, full-scale strategic programme, backed by EU defence funding, to secure the continent’s strategic autonomy and that anything less would be a grave miscalculation that could turn the Union's dependence on critical medicines into the Achilles’ heel of Europe’s security. In that context, it is essential that the Critical Medicines Act and the newly proposed Critical Medicines Security Fund act as robust instruments and that part of their funding be embedded in broader EU defence spending plans, including the financial mechanisms in the new Rearm Europe Plan.

Wording as published by the EP, in English. PE781.998

← Back to Main Vote
Status and procedure

Outcome as recorded by the European Parliament.

Vote held on
Latest recorded step
Committee stage · (122 days ago)
Next scheduled step
Plenary · (in 12 days)

Procedure timeline

2025/0102(COD) · COD

Recorded procedure activities. These do not establish whether a law has entered into force.

  1. Recorded: Referral58 days until the next step
  2. Recorded: Committee stage154 days until the next step
  3. Recorded: Plenary32 days until the next step
  4. Recorded: Negotiations175 days until the next step
  5. Latest recorded: Committee stage122 days since this step began
  6. Planned: Plenary
Recorded activities (25)
  1. Referral to committee
  2. Committee report tabled
  3. Committee amendments tabled
  4. Committee amendments tabled
  5. Committee amendments tabled
  6. Committee opinion adopted
  7. Committee opinion adopted
  8. Committee opinion adopted
  9. Committee report adopted
  10. Tabling for plenary
  11. Tabling for plenary
  12. Tabling for plenary
  13. Tabling for plenary
  14. Tabling for plenary
  15. Tabling for plenary
  16. Tabling for plenary
  17. Plenary debate
  18. Text amended in plenary
  19. Referred back to committee for interinstitutional negotiations
  20. Plenary vote
  21. Plenary vote results
  22. Interinstitutional negotiations
  23. Interinstitutional negotiations
  24. Interinstitutional negotiations
  25. Provisional agreement approved in committee
Scheduled activities (not confirmation of completion)
  1. Plenary debate
  2. Plenary vote
  3. Plenary vote

Procedure file (OEIL) · European Parliament data
Retrieved:

Sources

Data: EP Open Data API

What is this about?

  • This regulation seeks to enhance the security of supply and availability of critical medicines across the EU.
  • It establishes a framework to diversify supply chains and incentivize investments in local manufacturing capacities.
  • Special focus is placed on older, off-patent drugs through targeted financial support and streamlined approval processes.
  • Coordination among member states aims to reduce market fragmentation and strengthen the internal market.
  • The goal is to bolster the EU’s strategic autonomy in the healthcare sector.
Source: Explanatory Statement (AI Generated)

Vote by political group

How the political groups voted

Members

Showing 10 of 719

Vote Position
NameCountryGroupVote Position
SlovakiaNI
For
FranceGreens/EFA
For
GermanyS&D
For
GermanyNI
For
GermanyGreens/EFA
For
DenmarkGreens/EFA
For
SwedenGreens/EFA
For
SpainS&D
For
ItalyS&D
For
AustriaGreens/EFA
For
Show more
Follow us on Instagram@checksomevotes@checksomevotes_en